When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
NEW YORK (Reuters Health) – Treatment of prostate cancer with androgen deprivation therapy is associated with an excess risk of incident diabetes and fractures, but not MI or…
Joe Minniti, the Executive Director of the Cancer Foundation for Personal Appearance and Larry Cohen, Executive Vice President of the NIA Group, talk about the NIA group’s support…
Michael Banks, MD, provides an overview of diffuse brainstem gliomas. This video is dedicated to the memory of Max Scotti. About Making Headway Foundation Making Headway® is a…
NEW YORK (Reuters Health) – Initiating second-line chemotherapy for ovarian cancer recurrence based on an increase in the tumor marker CA125 alone does not improve overall survival compared…
NEW YORK (Reuters Health) – Most patients with synchronous metastatic (stage IV) colorectal cancer can forgo surgery to remove the primary tumor, at least initially, opting instead for…
NEW YORK (Reuters Health) – Rituximab (Rituxan) has been implicated in 57 cases of progressive multifocal leukoencephalopathy (PML) in HIV-negative patients diagnosed with hematologic malignancies or autoimmune diseases,…
NEW YORK (Reuters Health) – Combining hepatic artery infusion of floxuridine/dexamethasone with systemic oxaliplatin and irinotecan can make liver metastases from colorectal cancer resectable in about half of…
On April 22nd, 2009, people from around the globe gathered at US Cellular Field in Chicago to announce the Learning Living & Loving campaign. This call to action…
NEW YORK (Reuters Health) – Advanced prostate cancer appears to be of a more aggressive type when it occurs in young men, leading to dramatically higher cancer-specific mortality…
NEW YORK (Reuters Health) – In cancer patients accidentally overexposed with 5-fluorouracil (5-FU) chemotherapy, the investigational drug vistonuridine (Wellstat Therapeutics Corp) may be lifesaving, according to research to…
